publication venue for
- A Real-World Comparison of First-Line Regimens in Transplant Ineligible Patients with Multiple Myeloma 2024
- Durable Efficacy and Manageable Safety in Patients Aged ≥75 Years With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Treated With Tisagenlecleucel in the Real-World Setting 2024
- Comparative analysis of outcomes in patients with CRAB versus SLiM criteria at diagnosis of multiple myeloma 2023
- Development and validation of a prognostic survival model with patient reported outcomes for older adults with multiple myeloma 2023
- Outcomes of third-line therapy in multiple myeloma patients: a report from the Canadian myeloma research group (CMRG) 2023
- Rationale and design of three ongoing phase 1/2 trials of modakafusp alfa, an innate immunity enhancer, in patients with multiple myeloma: The innovate clinical development program 2023
- Real-world outcomes in myeloma patients with t(11;14): a matched comparison using the Canadian myeloma research group national clinical database 2023
- OAB-042: The impact of marginalization on treatment receipt and overall survival in newly diagnosed multiple myeloma patients in Ontario: a population-based cohort study 2022
- Outcomes of transplant-ineligible myeloma patients using bortezomib/lenalidomide-containing regimens in the real world: a report from the Canadian Myeloma Research Group Database 2022
- P-136: Global myeloma trial participation and drug access in the era of novel therapies 2022
- P-191: The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review 2022
- P-201: Outcomes of transplant-ineligible myeloma patients using bortezomib/lenalidomidecontaining regimens in the real world: a report from the Canadian Myeloma Research Group Database 2022
- P-261: Treatment attrition rates in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis 2022
- The impact of marginalization on treatment receipt and overall survival in Newly Diagnosed Multiple Myeloma patients in Ontario: A Population-Based Cohort Study. 2022
- The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review 2022
- Treatment attrition rates in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis 2022
- Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma 2021
- P-222: Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma 2021
- AML-303: Systematic Review of Frailty Assessment Tools for Elderly Patients with Acute Myeloid Leukemia 2020
- Systematic Review of Frailty Assessment Tools for Elderly Patients with Acute Myeloid Leukemia 2020
- Quality of Life Assessment in Older Patients with Newly-Diagnosed Multiple Myeloma 2019
- The role of bone marrow biopsy in patients with plasma cell disorders; should all patients with a monoclonal protein be biopsied? 2019
- Venetoclax For The Treatment of Translocation AL Amyloidosis 2019
- Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients 2019
- Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)—An Interim Analysis 2017
- GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA - AN INTERIM ANALYSIS 2017
- Let's Agree to Disagree: Reflections From the Smoldering Multiple Myeloma Session at the International Myeloma Society Study Summit.. 25:240-242. 2025
- First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline Consortium.. 25:e151-e172. 2025
- Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis.. S2152-2650(25)00073-4. 2025
- Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada.. S2152-2650(25)00020-5. 2025
- Durable Efficacy and Manageable Safety in Patients Aged ≥75 Years With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Treated With Tisagenlecleucel in the Real-World Setting. 24:s215. 2024
- MM-357 Systematic Literature Review and Meta-Analysis of Clinical Trials of Fourth Line or Higher Treatment for Relapsed/Refractory Multiple Myeloma Patients. 24:s551. 2024
- P-063 Systematic Literature Review and Meta-Analysis of Clinical Trials of Fourth Line or Higher Treatment for Relapsed/Refractory Multiple Myeloma Patients. 24:s77-s78. 2024
- P-161 Gut Microbiota Differences Among Transplant Ineligible Patients With Newly-Diagnosed Multiple Myeloma Treated With dara-len-dex. 24:s131-s132. 2024
- P-318 A Real-World Comparison of First-Line Regimens in Transplant Ineligible Patients with Multiple Myeloma. 24:s217-s218. 2024
- P-354 Real-World Comparison of Progression Free Survival and Time to Next Therapy Endpoints in Newly Diagnosed Patients With Multiple Myeloma. 24:s237-s238. 2024
- Systematic Literature Review and Meta-Analysis of Clinical Trials of Fourth Line or Higher Treatment for Relapsed/Refractory Multiple Myeloma Patients. 24:s237. 2024
- Pomalidomide Use and Kidney Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and Chronic Kidney Disease: A Real-World, Population-Based Cohort Study. 24:e861-e869. 2024
- Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. 24:e227-e234. 2024
- Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. 24:e130-e137. 2024
- Outcomes of Patients Treated With RCHOP With a PET-Adapted Approach for Consolidative Radiotherapy: A Retrospective Single-Center Study at the Royal Marsden Hospital. 24:48-54. 2024
- MCL-373 Unmet Need in Relapsed/Refractory (RR) Mantle Cell Lymphoma (MCL) Post-Bruton Tyrosine Kinase Inhibitor (BTKi): Systematic Literature Review and Meta-Analysis. 23:s461-s462. 2023
- OA-39 Development and validation of a prognostic survival model with patient reported outcomes for older adults with multiple myeloma. 23:S24-S24. 2023
- P-155 Comparative analysis of outcomes in patients with CRAB versus SLiM criteria at diagnosis of multiple myeloma. 23:S120-S121. 2023
- P-203 Rationale and design of three ongoing phase 1/2 trials of modakafusp alfa, an innate immunity enhancer, in patients with multiple myeloma: The innovate clinical development program. 23:S147-S147. 2023
- P-291 Outcomes of third-line therapy in multiple myeloma patients: a report from the Canadian myeloma research group (CMRG). 23:S197-S197. 2023
- P-321 Real-world outcomes in myeloma patients with t(11;14): a matched comparison using the Canadian myeloma research group national clinical database. 23:S215-S215. 2023
- POSTER: MCL-373 Unmet Need in Relapsed/Refractory (RR) Mantle Cell Lymphoma (MCL) Post-Bruton Tyrosine Kinase Inhibitor (BTKi): Systematic Literature Review and Meta-Analysis. 23:s212. 2023
- First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium. 23:340-354. 2023
- Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis. 23:127-137. 2023
- Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database. 22:608-617. 2022
- Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes. 21:e714-e721. 2021
- Burden of Treatment Among Older Adults With Newly Diagnosed Multiple Myeloma. 21:e152-e159. 2021
- Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma. 20:98-104.e1. 2020
- Geriatric Assessment and Frailty Scores Predict Mortality in Myeloma: Systematic Review and Meta-analysis. 19:488-496.e6. 2019
- The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma. 18:829-835. 2018
- Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up. 17:870-878.e1. 2017
- Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. 16:18-28.e4. 2016
- Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. 15:715-727. 2015
- Lenalidomide Plus Melphalan Without Prednisone for Previously Untreated Older Patients With Multiple Myeloma: A Phase II Trial. 13:19-24. 2013
- 5.29 Potential of AFX-2, a Unique, Polysaccharide-Based Toll-like Receptor Agonist, in Patients With Chronic Lymphocytic Leukemia. 11:S262-S263. 2011
- Bortezomib in Relapsed or Refractory Waldenström's Macroglobulinemia. 9:74-76. 2009